{"id":5193,"date":"2020-02-02T13:59:40","date_gmt":"2020-02-02T04:59:40","guid":{"rendered":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/contents\/?p=5193"},"modified":"2020-02-02T13:59:40","modified_gmt":"2020-02-02T04:59:40","slug":"2019%e5%b9%b4%e6%a5%ad%e7%b8%be%e3%80%80%e3%81%9d%e3%81%ae2","status":"publish","type":"post","link":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/%e7%a0%94%e7%a9%b6%e7%b4%b9%e4%bb%8b\/5193\/","title":{"rendered":"2019\u5e74\u696d\u7e3e\u3000\u305d\u306e2"},"content":{"rendered":"

2019\u5e74\u696d\u7e3e\u3000\u305d\u306e2
\n\u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09<\/a>
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/a>
\n\u25a0 \u8b1b\u6f14<\/a>
\n\u25a0 \u7814\u7a76\u52a9\u6210<\/a>
\n\u25a0 \u53d7\u8cde<\/a>
\n\u8ad6\u6587\u3001\u56fd\u969b\u5b66\u4f1a\u767a\u8868\u306f2019\u5e74\u696d\u7e3e\u3000\u305d\u306e1<\/a>\u3092\u3054\u89a7\u4e0b\u3055\u3044\u3002
\n 
\n\u25a0<\/span> \u5b66\u4f1a\u767a\u8868(\u56fd\u5185)<\/strong>
\n<\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a(\u5168\u56fd)<\/p>\n

    \n
  1. \u57ce\u6238\u8f1d\u4ec1\uff0eCT Perfusion\u3092\u7528\u3044\u305f\u975e\u4fb5\u8972\u7684\u865a\u8840\u8a55\u4fa1\u3092\u8ffd\u6c42\u3059\u308b\uff0e\u7b2c\uff12\uff19\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff082019\uff0e1\uff0c\u4e45\u7559\u7c73\uff09<\/li>\n
  2. \u5ddd\u53e3\u76f4\u4eba\u3001\u5ca1\u5c71\u82f1\u6a39\u3001\u798f\u5c71\u76f4\u7d00\u3001\u7530\u908a\u88d5\u8cb4\u3001\u677e\u7530\u5353\u4e5f\u3001\u57ce\u6238\u502b\u4e4b\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u5009\u7530\u8056\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00. \u865a\u8840\u6027\u5fc3\u75be\u60a3\u306b\u304a\u3051\u308bN-13 \u30a2\u30f3\u30e2\u30cb\u30a2PET\u3068\u5fc3\u81d3CT\u3092\u7528\u3044\u305fCorrected Relative Flow Reserve\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e. \u00a0\u7b2c29\u56de \u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a (2019.1, \u4e45\u7559\u7c73)<\/li>\n
  3. \u5409\u7530\u548c\u6a39\u3001\u7530\u908a\u88d5\u8cb4\u3001\u6cb3\u5185\u7fa9\u5f18\u3001\u6851\u539f\u5948\u90fd\u7f8e\u3001\u6cb3\u5185\u5b5d\u7bc4\u3001\u5e73\u4e95\u90a6\u660e, \u677e\u7530\u5353\u4e5f\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u5009\u7530\u8056\u3001\u57ce\u6238\u502b\u4e4b\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00. \u5e0c\u91c8\u9020\u5f71\u6cd5\u3092\u7528\u3044\u305f\u51a0\u52d5\u8108 CT \u306b\u304a\u3051\u308b\u30d7\u30e9\u30fc\u30af\u6027\u72b6\u3068 IB-IVUS \u306e\u6bd4\u8f03\u691c\u8a0e. \u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a (2019.1 \u4e45\u7559\u7c73)<\/li>\n
  4. \u5e73\u4e95\u90a6\u660e, \u57ce\u6238\u502b\u4e4b, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. compressed sensing\u3092\u7528\u3044\u305fcoronary MRA\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e. \u7b2c88\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a (2019. 1, \u798f\u5ca1)<\/li>\n
  5. \u6cb3\u5185\u5b5d\u7bc4, \u7530\u9089\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u5409\u7530\u548c\u6a39, \u5e73\u4e95\u90a6\u660e, \u677e\u7530\u5353\u4e5f, \u5ddd\u53e3\u76f4\u4eba, \u57ce\u6238\u502b\u4e4b, \u5009\u7530\u8056, \u671b\u6708\u8f1d\u4e00. \u5fc3\u7b4bCT perfusion\u306b\u3088\u308b\u865a\u8840\u8a55\u4fa1\u306b\u304a\u3051\u308bSimulated enhancement ratio of myocardium to aorta\u306e\u6709\u7528\u6027. \u7b2c88\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a (2019.1 \u718a\u672c)<\/li>\n
  6. \u6a2a\u4e95\u656c\u5f18, \u4e09\u6728\u5747, \u4e95\u4e0a\u6b66, \u5ca9\u7530\u771f\u6cbb, \u5927\u4e0a\u53f2\u6717. \u5185\u8996\u93e1\u4e0b\u7b2c\u4e09\u8133\u5ba4\u5e95\u958b\u7a93\u8853\u5f8c\u306b\u304a\u3051\u308b3D-SPACE\u6cd5\u3092\u7528\u3044\u305f\u30b9\u30c8\u30fc\u30de\u958b\u5b58\u6027\u306e\u753b\u50cf\u8a55\u4fa1. \u7b2c48\u56de\u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a (2019. 2, \u4e45\u7559\u7c73)<\/li>\n
  7. \u6cb3\u5185\u5b5d\u7bc4, \u7530\u9089\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u6851\u539f\u5948\u90fd\u7f8e, \u5409\u7530\u548c\u6a39, \u5e73\u4e95\u90a6\u660e, \u677e\u7530\u5353\u4e5f, \u5ddd\u53e3\u76f4\u4eba, \u57ce\u6238\u502b\u4e4b,\u5009\u7530\u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u5fc3\u7b4bCT perfusion\u306b\u3088\u308b\u865a\u8840\u8a55\u4fa1\u306b\u304a\u3051\u308bSimulated enhancement ratio of myocardium to aorta\u306e\u6709\u7528\u6027. FRIENDS Live 2019 (2019.2 \u6771\u4eac)<\/li>\n
  8. \u677e\u7530\u3000\u6075, \u6d25\u7530\u3000\u5b5d\u6cbb, \u57ce\u6238\u3000\u8f1d\u4ec1,\u3000\u897f\u5c71\u3000\u5149, \u671b\u6708\u3000\u8f1d\u4e00.\u4e73\u764c\u306e\u514d\u75ab\u7d44\u7e54\u5316\u5b66\u6240\u898b\u63a8\u5b9a\u306b\u304a\u3051\u308bDual energy CT\u3092\u7528\u3044\u3066\u5f97\u3089\u308c\u305fIodine map\u306b\u3088\u308b\u30e8\u30fc\u30c9\u5b9a\u91cf\u306e\u6709\u7528\u6027.\u3000\u7b2c28\u56de\u65e5\u672c\u4e73\u764c\u753b\u50cf\u7814\u7a76\u4f1a.\uff08 02, \u4ed9\u53f0\uff09<\/li>\n
  9. \u5175\u982d\u670b\u5b50, \u67f3\u751f\u884c\u4f38, \u6cb3\u91ce\u96c4\u8f1d, \u6cbc\u672c\u52f2, \u9db4\ufa11\u6b63\u52dd, \u4e0a\u5d8b\u4e00\u81e3, \u5de5\u85e4\u6b63\u4fca, \u77f3\u4e95\u4e00\u6210 . conventional TACE\u306e\u30e8\u30fc\u30c9\u5bc6\u5ea6\u753b\u50cf\u306b\u3088\u308b\u6cbb\u7642\u52b9\u679c\u5224\u5b9a.\u00a0\u00a0\u7b2c25\u56de\u809d\u8840\u6d41\u52d5\u614b\u30fb\u6a5f\u80fd\u30a4\u30e1\u30fc\u30b8\u7814\u7a76\u4f1a (2019\u5e742\u6708, \u6771\u4eac)<\/li>\n
  10. \u5409\u7530 \u548c\u6a39\u3001\u7530\u908a \u88d5\u8cb4\u3001\u6cb3\u5185 \u7fa9\u5f18\u3001\u6cb3\u5185 \u5b5d\u7bc4\u3001\u5009\u7530 \u8056\u3001\u57ce\u6238 \u8f1d\u4ec1\u3001\u671b\u6708 \u8f1d\u4e00. \u5e0c\u91c8\u9020\u5f71\u6cd5\u3092\u7528\u3044\u305f\u51a0\u52d5\u8108 CT \u306b\u304a\u3051\u308b\u30d7\u30e9\u30fc\u30af\u6027\u72b6\u3068 IB-IVUS \u306e\u6bd4\u8f03\u691c\u8a0e. FRIENDS Live 2019 (2019.3 \u6771\u4eac)<\/li>\n
  11. \u7530\u4e2d\u5b8f\u660e,\u5ddd\u53e3\u76f4\u4eba,\u6d25\u7530\u5b5d\u6cbb,\u671b\u6708\u8f1d\u4e00,\u798f\u5c71\u76f4\u7d00. \u6b63\u4e2d\u5f13\u72b6\u9771\u5e2f\u5727\u8feb\u75c7\u5019\u7fa4\u306b\u4f34\u3046\u81b5\u5341\u4e8c\u6307\u8178\u52d5\u8108\u7624\u7834\u88c2\u306b\u3066\u30b3\u30a4\u30eb\u585e\u6813\u3068\u30b9\u30c6\u30f3\u30c8\u6cbb\u7642\u3092\u540c\u6642\u306b\u65bd\u884c\u3057\u305f1\u4f8b. \u7b2c55\u56de\u65e5\u672c\u8179\u90e8\u6551\u6025\u533b\u5b66\u4f1a\u7dcf\u4f1a(2019.3.\u4ed9\u53f0)<\/li>\n
  12. \u4e09\u6728\u3000\u5747.\u3000\u810a\u9ac4\u816b\u760d\u306e\uff11\u4f8b.\u3000\u7b2c11\u56de\u810a\u690e\u30fb\u810a\u9ac4\u753b\u50cf\u30af\u30e9\u30d6 \uff083,\u54c1\u5ddd\uff09<\/li>\n
  13. \u57ce\u6238\u8f1d\u4ec1\uff0e Complementary Diagnosis in Treatment Strategy of Ischemic Heart Disease\uff0e\u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff082019\uff0e4\uff0c\u6771\u4eac\uff09<\/li>\n
  14. Hitomi Ochi, Natsumi Kuwahara, Teruhito Kido, Yuki Tanabe, Akira Kurata, Hikaru Nishiyama, Masao Miyagawa, Teruhito Mochizuki, et al. Coronary artery calcification score on evaluating coronary artery disease prevalence in Japanese population. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019. 4, \u6a2a\u6d5c)<\/li>\n
  15. Yoshihiro Kouchi, Kazuki Yoshida, Yuki Tanabe, Takanori Kouchi, Teruhito Kido, Akira Kurata, Teruhito Mochizuki. Comparison of Plaque Characteristics Between Coronary Computed Tomography Angiography Based on Diluted Contrast-Injection Protocol and Integrated Backscatter Intravascular Ultrasound. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff08 4, \u6a2a\u6d5c\uff09<\/li>\n
  16. Hosokawa T, Kouchi T, Tanabe Y, Kido T, Kuwahara N, Yoshida K, Kido T, Kurata A, Mochizuki T, Uetani T, Yamaguchi O. The Utility of myocardial color scale for detection of obstructive coronary artery disease using dynamic myocardial computed tomography perfusion. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019.4.12-14, \u6a2a\u6d5c)<\/li>\n
  17. Matsuda M, Tsuda T, Hiratsuka Y, Kido T, Shiraishi Y, Suekuni H, Mochizuki T.Quantitative evaluation in the breast lesions using synthetic MRI: differences between benign and malignant lesions. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a(2019. 04, \u6a2a\u6d5c)<\/li>\n
  18. Tsuruoka S, Kataoka M, Hamamoto Y, Ouchi A, Ishikawa H, Takata N, Mochizuki T. Outcomes after treatment for recurrence in patients with locally advanced cervical cancer\uff0e\u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019. 4, \u6a2a\u6d5c)<\/li>\n
  19. Takanori Kouchi, Yuki Tanabe, Teruhito Kido, Natsumi Kuwahara, Kazuki Yoshida, Tomoyuki Kido, Akira Kurata, Teruhito Mochizuki. Simulated enhancement ratio of myocardium to aorta for identification of obstructive coronary artery disease using dynamic myocardial computed tomography perfusion. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019.4 \u795e\u5948\u5ddd)<\/li>\n
  20. Kazuki Yoshida, Yuki Tanabe, Daichi Uraoka, Takanori Kouchi, Natsumi Kuwahara, Teruhito Kido, Akira Kurata, Teruhito Mochizuki. Regional Left Ventricular Three Dimensional Maximum Principal Strain Measurements from Cardiac Computed Tomography in Patients with Normal LV function. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a(2019.4 \u6a2a\u6d5c)<\/li>\n
  21. Kawaguchi N, Fukuyama N, Kido To, Kurata A, Kido Te, Inoue T, Miki H, Miyagawa M, Mochizuki T, et al., et al.Corrected Relative Flow Reserve Derived from N-13 ammonia PET Combined with Coronary CT Angiography for the Assessment of Regional Ischemic Perfusion \u7b2c78\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019.4, \u6a2a\u6d5c)<\/li>\n
  22. \u6e21\u90e8\u3000\u7b11\u9e97\uff0c\u5bae\u5ddd\u3000\u6b63\u7537, \u77f3\u6751\u3000\u96bc\u4eba, \u5ddd\u53e3\u3000\u76f4\u4eba, \u671b\u6708\u3000\u8f1d\u4e00\uff0eFDG\u6ce8\u5c04\u524d\u306e\u8840\u6db2\u30b5\u30f3\u30d7\u30ea\u30f3\u30b0\u306b\u3088\u308b\u5fc3\u81d3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u60a3\u8005\u306b\u304a\u3051\u308b\u751f\u7406\u5b66\u7684\u5fc3\u7b4b\u53d6\u308a\u8fbc\u307f\u306e\u6291\u5236\u4e88\u6e2c\uff0e\u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082019\uff0e4\uff0c\u6a2a\u6d5c\uff09<\/li>\n
  23. \u7267\u7530\u61b2\u4e8c, \u6ff1\u672c\u6cf0, \u6d66\u5cf6\u96c4\u4ecb, \u9ad8\u7530\u7d00\u5b50, \u83ca\u6c60\u6075\u4e00, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. The relationship of external beam radiotherapy and radioactive iodine for metastatic lesions of well-differentiated thyroid cancer. \u7b2c78\u56de\u3000\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019. 4, \u6a2a\u6d5c)<\/li>\n
  24. \u798f\u5c71\u76f4\u7d00\u3001\u4e09\u6728\u5747\u3001\u9ad8\u5ca1\u6709\u7d00\u5b50\u3001\u4e2d\u9808\u8cc0\u4f73\u592e\u91cc\u3001\u5e74\u68ee\u65e6\u3001\u9ad8\u9580\u653f\u5609\u3001\u6a2a\u4e95\u656c\u5f18\u3001\u68ee\u5343\u5c0b\u3001\u6751\u4e0a\u5fe0\u53f8\u3001\u677e\u6728\u5f18\u91cf\u3001\u77f3\u4e38\u826f\u5e83\u3001\u9ad9\u6a4b\u5fe0\u7ae0\u3001\u4e95\u4e0a\u6b66.The evaluation of MRI findings in old lacunar infarction: A follow-up study \u6162\u6027\u671f\u30e9\u30af\u30ca\u6897\u585e\u306eMRI\u6240\u898b\u306e\u691c\u8a0e\uff1a\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u30b9\u30bf\u30c7\u30a3\u30fc. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff084,\u6a2a\u6d5c\uff09<\/li>\n
  25. \u5e73\u4e95\u90a6\u660e, \u57ce\u6238\u502b\u4e4b, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. compressed sensing\u3092\u7528\u3044\u305fcoronary MRA\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019. 4, \u6771\u4eac)<\/li>\n
  26. \u798f\u5c71\u76f4\u7d00\u3001\u77f3\u4e38\u826f\u5e83\u3001\u5e74\u68ee\u65e6\u3001\u4e2d\u9808\u8cc0\u4f73\u592e\u91cc\u3001\u9ad8\u9580\u653f\u5609\u3001\u6a2a\u4e95\u656c\u5f18\u3001\u6751\u4e0a\u5fe0\u53f8\u3001\u4e95\u4e0a\u6b66\u3001\u4e09\u6728\u5747. \u5f53\u9662\u306b\u304a\u3051\u308b\u30d0\u30b9\u30ad\u30e5\u30e9\u30fc\u30a2\u30af\u30bb\u30b9\u6025\u6027\u9589\u585e\u306b\u5bfe\u3059\u308bVAIVT\u6cbb\u7642\u6210\u7e3e\u306e\u691c\u8a0e. \u7b2c48\u56de\u65e5\u672cIVR\u5b66\u4f1a\u7dcf\u4f1a\uff085,\u798f\u5ca1\uff09<\/li>\n
  27. \u7530\u4e2d\u5b8f\u660e\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u671b\u6708\u8f1d\u4e00.\u526f\u813e\u306b\u5408\u4f75\u3057\u305f\u51fa\u8840\u6027\u6897\u585e\u306b\u5bfe\u3057\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f1\u4f8b.\u7b2c48\u56de\u65e5\u672cIVR\u5b66\u4f1a\u7dcf\u4f1a(2019.5.\u798f\u5ca1)<\/li>\n
  28. IVR\u306b\u5f79\u7acb\u3064\u30a2\u30d7\u30ea\u958b\u767a
    \n\u5e73\u7530 \u96c5\u662d(\u677e\u5c71\u5e02\u6c11\u75c5\u9662 \u653e\u5c04\u7dda\u79d1), \u5ca9\u91ce \u7965\u5b50, \u4e2d\u6751 \u8aa0\u6cbb, \u8d64\u5b97 \u660e\u4e45, \u6e21\u908a \u826f\u5e73
    \n\u7b2c48\u56de\u65e5\u672c\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30ca\u30eb\u30e9\u30b8\u30aa\u30ed\u30b8\u30fc\u5b66\u4f1a\u7dcf\u4f1a(2019. 5, \u798f\u5ca1)<\/li>\n
  29. \u5ca9\u91ce \u7965\u5b50(\u6c38\u983c\u4f1a\u677e\u5c71\u5e02\u6c11\u75c5\u9662 \u653e\u5c04\u7dda\u79d1), \u5e73\u7530 \u96c5\u662d, \u4e2d\u6751 \u8aa0\u6cbb, \u8d64\u5b97 \u660e\u4e45, \u7530\u4e2d \u826f\u61b2, \u6e21\u908a \u826f\u5e73.\u00a0AVP2\u7559\u7f6e\u5358\u72ec\u3067\u306f\u4e0d\u5341\u5206\u3067\u3042\u3063\u305f\u305f\u3081\u30d7\u30e9\u30b0\u5185\u3092\u30b3\u30a4\u30eb\u585e\u6813\u3057\u305f\u732a\u702c\u578b\u809d\u6027\u8133\u75c7\u306e1\u4f8b.\u00a0\u7b2c48\u56de\u65e5\u672c\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30ca\u30eb\u30e9\u30b8\u30aa\u30ed\u30b8\u30fc\u5b66\u4f1a\u7dcf\u4f1a(2019. 5, \u798f\u5ca1)<\/li>\n
  30. \u5ca9\u91ce \u7965\u5b50(\u6c38\u983c\u4f1a\u677e\u5c71\u5e02\u6c11\u75c5\u9662 \u653e\u5c04\u7dda\u79d1), \u5e73\u7530 \u96c5\u662d, \u4e2d\u6751 \u8aa0\u6cbb, \u8d64\u5b97 \u660e\u4e45, \u7530\u6751 \u5468\u592a, \u6e21\u908a \u826f\u5e73.\u00a0Biloma\u3078\u306e\u7d4c\u76ae\u7684\u306a\u30c9\u30ec\u30fc\u30f3\u7d4c\u8def\u3092\u5fdc\u7528\u3057\u3066\u5185\u763b\u5316\u3067\u304d\u305f\u7dcf\u80c6\u7ba1\u65ad\u88c2\u306e1\u4f8b.\u00a0\u7b2c48\u56de\u65e5\u672c\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30ca\u30eb\u30e9\u30b8\u30aa\u30ed\u30b8\u30fc\u5b66\u4f1a\u7dcf\u4f1a(2019. 5, \u798f\u5ca1)<\/li>\n
  31. \u5ca1\u7530\u3000\u52a0\u5948\u5b50\u3001\u677e\u7530\u3000\u6075\u3001\u6d77\u8001\u539f\u3000\u308b\u3044\u3001\u6d25\u7530\u3000\u5b5d\u6cbb\u3001\u7530\u4e2d\u3000\u5b8f\u660e\u3001\u671b\u6708\u3000\u8f1d\u4e00.\u3000\u809d\u6d78\u6f64\u3092\u4f34\u3063\u305f\u597d\u9178\u7403\u5897\u591a\u75c7\u306e1\u4f8b.\u7b2c33\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a(2019. 6, \u5c71\u53e3)<\/li>\n
  32. \u6d77\u8001\u539f\u308b\u3044,\u677e\u7530 \u6075,\u00a0\u6d25\u7530 \u5b5d\u6cbb,\u00a0\u5ca1\u7530 \u52a0\u5948\u5b50,\u00a0\u7530\u4e2d \u5b8f\u660e,\u00a0\u671b\u6708 \u8f1d\u4e00.\u809d\u8ee2\u79fb\u306e\u7834\u88c2\u3092\u304d\u305f\u3057\u305f\u80f8\u817a\u816b\u306e1\u4f8b.\u7b2c33\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a(2019. 6,\u00a0\u5c71\u53e3)<\/li>\n
  33. \u7d30\u5ddd\u6d69\u5e73\uff0c\u83c5\u539f\u656c\u6587\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u89d2\u7530\u4fca\u96c4\uff0c\u6a4b\u6839\u52dd\u7fa9\uff0c\u5409\u7530\u529f\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u7cbe\u5de3\u4e0a\u4f53\u816b\u7624\u3092\u5951\u6a5f\u306b\u767a\u898b\u3055\u308c\u305f\u60aa\u6027\u30ea\u30f3\u30d1\u816b\u306e1\u4f8b\uff0e\u7b2c33\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2019.6.28-29, \u4e0b\u95a2)<\/li>\n
  34. \u5fb3\u6c38\u4f38\u5b50\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u53cb\u91ce\u52dd\u5e78\uff0c\u7af9\u539f\u548c\u5b8f\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u81ea\u7136\u9000\u7e2e\u3092\u6765\u3057\u305f\u5b50\u5bae\u4f53\u764c\u306e\uff11\u4f8b\uff0e\u7b2c33\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2019.6.28-29, \u4e0b\u95a2)<\/li>\n
  35. \u7af9\u53e3\u5d07, \u6751\u7530\u771f\u592e, \u5ca9\u6751\u5353\u660e, \u539f\u4e95\u5ddd\u8c4a\u7ae0, \u798f\u4e95\u8061, \u897f\u60a0\u4ecb, \u677e\u5f71\u662d\u4e00. \u526f\u813e\u51fa\u8840\u6027\u6897\u585e\u7834\u88c2\u306e\uff11\u4f8b. \u7b2c33\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2019. 6, \u938c\u5009)<\/li>\n<\/ol>\n

     <\/p>\n

      \n
    1. \u795e\u5d0e\u535a\u5145, Flexitron\u521d\u671f\u4f7f\u2f64\u7d4c\u9a13, \u30de\u30a4\u30af\u30ed\u30ec\u30af\u30c8\u30ed\u30f3HDR\u7814\u7a76\u4f1a\u7b2c15\u56de\u5b66\u8853\u7814\u7a76\u4f1a\uff08 7, \u6771\u4eac\uff09<\/li>\n
    2. \u5ca1\u7530\u3000\u52a0\u5948\u5b50\u3001\u677e\u7530 \u6075\u3001\u6d25\u7530\u3000\u5b5d\u6cbb\u3001\u57ce\u6238\u3000\u8f1d\u4ec1\u3001\u897f\u5c71\u3000\u5149\u3001\u671b\u6708\u3000\u8f1d\u4e00. \u4e73\u764c\u306e\u514d\u75ab\u7d44\u7e54\u5316\u5b66\u6240\u898b\u63a8\u5b9a\u306b\u304a\u3051\u308bDual energy CT\u3092\u7528\u3044\u3066\u5f97\u3089\u308c\u305fIodine map\u306b\u3088\u308b\u30e8\u30fc\u30c9\u5b9a\u91cf\u306e\u6709\u7528\u6027. Society of Advanced Medical Imaging(SAMI)2019 (2019. 7, \u5927\u962a)<\/li>\n
    3. \u5409\u7530\u548c\u6a39\u3001\u7530\u908a\u88d5\u8cb4\u3001\u6cb3\u5185\u5b5d\u7bc4\u3001\u5e73\u4e95\u90a6\u660e\u3001\u5c71\u672c\u96c4\u592a\u3001\u6851\u539f\u5948\u90fd\u7f8e\u3001\u677e\u7530\u5353\u4e5f\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u57ce\u6238\u502b\u4e4b\u3001\u5009\u7530\u8056\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u671b\u6708\u8f1d\u4e00. \u30c0\u30a4\u30ca\u30df\u30c3\u30af\u5fc3\u7b4b CT perfusion\u3092\u7528\u3044\u305f Myocardial blood volume\u306e\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306b\u5bfe\u3059\u308b\u6709\u7528\u6027\u306b\u3064\u3044\u3066. \u7b2c4\u56deSociety of Advanced Medical Imaging\u7814\u7a76\u4f1a (2019.7 \u5927\u962a)<\/li>\n
    4. \u798f\u5c71\u76f4\u7d00\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u4e09\u6728\u5747. \u5e0c\u91c8\u9020\u5f71\u6cd5\u3092\u7528\u3044\u305f\u51a0\u52d5\u8108CT\u306b\u304a\u3051\u308b\u51a0\u52d5\u8108\u9020\u5f71\u52b9\u679c\u306e\u518d\u73fe\u6027\u306e\u691c\u8a0e. SAMI2019\uff087,\u5927\u962a\uff09<\/li>\n
    5. \u5ca1\u7530\u77e5\u4e45,\u5bae\u5ddd\u6b63\u7537,\u5ddd\u53e3\u76f4\u4eba,\u7530\u9089\u88d5\u8cb4,\u4e2d\u6751\u58ee\u5fd7,\u677e\u7530\u5353\u4e5f,\u57ce\u6238\u502b\u4e4b,\u57ce\u6238\u8f1d\u4ec1,\u3000\u5009\u7530\u8056,\u671b\u6708\u8f1d\u4e00. \u5fc3\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u306b\u304a\u3051\u308b\u5fc3\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u306b\u304a\u3051\u308bFDG PET \u306e\u691c\u8a0e.\u7b2c89\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a(2019.7, \u6771\u4eac)<\/li>\n
    6. \u7530\u908a\u3000\u88d5\u8cb4<\/u>\u3001\u57ce\u6238\u3000\u8f1d\u4ec1\u3001\u5009\u7530\u3000\u8056\u3001\u5409\u7530\u3000\u548c\u6a39\u3001\u6cb3\u5185\u3000\u5b5d\u7bc4\u3001\u5ddd\u53e3\u3000\u76f4\u4eba\u3001\u57ce\u6238\u3000\u502b\u4e4b\u3001\u671b\u6708\u3000\u8f1d\u4e00\u3002\u5fc3\u81d3CT\u3092\u7528\u3044\u305fGlobal 3-D maximum principal strain\u30682-D speckle-tracking echocardiography\u3068\u306e\u6bd4\u8f03\u691c\u8a0e\u3002\u7b2c89\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff087,\u6771\u4eac\uff09<\/li>\n
    7. \u5ddd\u53e3\u76f4\u4eba1)\u3001\u798f\u5c71\u76f4\u7d00\u3001\u7530\u908a\u88d5\u8cb4\u3001\u677e\u7530\u5353\u4e5f\u3001\u57ce\u6238\u502b\u4e4b\u3001\u57ce\u6238\u8f1d\u4ec1 \u3001\u5009\u7530\u8056\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00.\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306b\u304a\u3051\u308bN-13 \u30a2\u30f3\u30e2\u30cb\u30a2 PET\u5fc3\u81d3CT\u3092\u7528\u3044\u305fCorrected Relative Flow Reserve\u306e\u81e8\u5e8a\u7684\u6709\u7528\u6027\u306e\u691c\u8a0e \u7b2c29\u56de \u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u5b66\u4f1a\u7dcf\u4f1a (2019.7, \u51fd\u9928)<\/li>\n
    8. \u77f3\u6751\u96bc\u4eba\u3001\u5927\u897f\u606d\u5e73\u3001\u5b88\u5c4b\u3000\u5065\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3\u5c02\u7528\u534a\u5c0e\u4f53SPECT\u88c5\u7f6e\u306b\u304a\u3051\u308b\u5fc3\u81d3\u7e26\u9694\u6bd4\u7b97\u51fa\u306e\u691c\u8a0e\u3000\uff5eI-123\u6838\u7a2e\u3068\u5fc3\u81d3\u809d\u81d3\u30d5\u30a1\u30f3\u30c8\u30e0\u3092\u7528\u3044\u3066\uff5e.\u7b2c29\u56de \u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\u3000(2019. 7, \u51fd\u9928)<\/li>\n
    9. \u6771\u91ce \u535a\u3001\u9e7f\u5cf6 \u6587\u3001\u8c9e\u5fb3 \u307f\u3061\u3053\u3001\u5bae\u7530 \u60a0\u91cc\u3001\u8535\u7530 \u65e9\u7d00\u3001\u4e2d\u7530 \u8302\u3001\u6c60\u6c34 \u6681\u5f66\u3001\u5ddd\u6761 \u6587\u9686\u3001\u4f0a\u7530 \u52dd\u5178\u3001\u7530\u4e2d \u653f\u884c\u3001\u963f\u90e8 \u5145\u4f2f. \u653e\u5c04\u6027\u533b\u85ac\u54c1\u3068\u7a7a\u6e2f\u30bb\u30ad\u30e5\u30ea\u30c6\u30a3: \u30bf\u30ea\u30a6\u30e0\u5fc3\u7b4b\u30b7\u30f3\u30c1\u30b0\u30e9\u30d5\u30a3\u30fc\u691c\u67fb\u5f8c\u306b\u56fd\u969b\u7a7a\u6e2f\u3067\u4e8b\u60c5\u3092\u8074\u53d6\u3055\u308c\u305f\u4e00\u4f8b. \u7b2c29\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\u3001\u30d5\u30a9\u30fc\u30dd\u30a4\u30f3\u30c8\u30d0\u30a4\u30b7\u30a7\u30e9\u30c8\u30f3\u51fd\u9928\u30012019\u5e747\u670813\u65e5.<\/li>\n
    10. \u5ca1\u7530\u77e5\u4e45\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u7530\u9089\u88d5\u8cb4\u3001\u4e2d\u6751\u58ee\u5fd7\u3001\u677e\u7530\u5353\u4e5f\u3001\u57ce\u6238\u502b\u4e4b\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u5009\u7530\u3000\u8056\u3001\u671b\u6708\u8f1d\u4e00. \u9577\u6642\u9593\u7d76\u98dfPET\u30d7\u30ed\u30c8\u30b3\u30fc\u30eb\u3067\u64ae\u5f71\u3057\u305f\u5fc3\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u306b\u304a\u3051\u308bFDG\u96c6\u7a4d\u306e\u691c\u8a0e. \u7b2c29\u56de \u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\u3000(2019. 7, \u51fd\u9928)<\/li>\n
    11. \u5009\u7530\u8056\uff0e\uff08\u6307\u540d\u8b1b\u6f14\uff09\u65e5\u5faa\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306e\u6539\u8a02\uff0e\u7b2c 13 \u56de SCCT \u7814\u7a76\u4f1a\uff082019, 9 \u6708, \u6771\u4eac\uff09<\/li>\n
    12. \u5409\u7530\u548c\u6a39\u3001\u7530\u908a\u88d5\u8cb4\u3001\u6851\u539f\u5948\u90fd\u7f8e\u3001\u5ca1\u7530\u77e5\u4e45\u3001\u6cb3\u5185\u5b5d\u7bc4\u3001\u5e73\u4e95\u90a6\u660e\u3001\u5c71\u672c\u96c4\u592a\u3001\u4e2d\u6751\u58ee\u5fd7\u3001\u677e\u7530\u5353\u4e5f\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u5009\u7530\u8056\u3001\u57ce\u6238\u502b\u4e4b\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00. \u5de6\u5ba4\u5fc3\u6a5f\u80fd\u6b63\u5e38\u60a3\u8005\u306b\u304a\u3051\u308b\u3001\u5fc3\u81d3CT\u304b\u3089\u7b97\u51fa\u3057\u305f\u5de6\u5ba4\u5fc3\u7b4b3D maximum principal strain (3D-MPS) \u306e\u691c\u8a0e. \u7b2c13\u56deSCCT\u7814\u7a76\u4f1a. (2019.9 \u6771\u4eac)<\/li>\n
    13. \u7d30\u5ddd\u8cb4\u6676, \u5fb7\u6c38\u4f38\u5b50, \u7d30\u5ddd\u6d69\u5e73, \u6850\u5c71\u90c1\u5b50, \u6e05\u6c34\u8f1d\u5f66, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u53cb\u91ce\u52dd\u5e78, \u7af9\u539f\u548c\u5b8f, \u5bfa\u672c\u5178\u5f18. \u81ea\u7136\u9000\u7e2e\u3092\u6765\u3057\u305f\u5b50\u5bae\u4f53\u764c\u306e\uff11\u4f8b. JSAWI2019, 20th Annual Symposium (2019.9.6-7, \u6de1\u8def)<\/li>\n
    14. \u5ca1\u7530\u52a0\u5948\u5b50\u3001\u677e\u7530\u3000\u6075\u3001\u6d25\u7530\u3000\u5b5d\u6cbb\u3001\u767d\u77f3\u3000\u6cf0\u5b8f\u3001\u672b\u56fd\u3000\u5b8f\u3001\u671b\u6708\u3000\u8f1d\u4e00.Hepatobiliary phase of gadoxetic acid-enhanced MRI using combined parallel imaging and compressed sensing compared with conventional method. EOB\u9020\u5f71MRI\u306b\u304a\u3051\u308bCompressed sensing\u306e\u6709\u7528\u6027-CS\u4f75\u7528\u3068\u901a\u5e38\u64ae\u5f71\u3068\u306e\u6bd4\u8f03-\u3000\u7b2c48\u56de\u65e5\u672c\u6838\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a\uff08 9, \u718a\u672c\uff09<\/li>\n
    15. \u798f\u5c71\u76f4\u7d00\u3001\u4e09\u6728\u5747\u3001\u4e09\u6a4b\u907c\u592a\u3001\u6cb3\u5185\u7fa9\u5f18\u3001\u5e74\u68ee\u65e6\u3001\u4e2d\u9808\u8cc0\u3001\u5fb3\u5897\u660e\u6587\u3001\u5c0f\u5ca9\u539f\u5143\u3001\u68ee\u5343\u5c0b\u3001\u6751\u4e0a\u5fe0\u53f8\u3001\u677e\u6728\u5f18\u91cf\u3001\u77f3\u4e38\u826f\u5e83\u3001\u9ad9\u6a4b\u5fe0\u7ae0\u3001\u4e95\u4e0a\u6b66. \u6162\u6027\u671f\u30e9\u30af\u30ca\u6897\u585e\u306e\u691c\u51fa\u7387\uff1aT1W-SE\u3068T1-FLAIR\u306e\u6bd4\u8f03. \u7b2c47\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a\uff089,\u718a\u672c\uff09<\/li>\n
    16. \u5e73\u4e95\u90a6\u660e, \u57ce\u6238\u502b\u4e4b, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. compressed sensing\u3092\u7528\u3044\u305fcoronary MRA\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e. \u7b2c47\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a<\/em>\u5927\u4f1a (2019. 9, \u718a\u672c)<\/li>\n
    17. \u5c71\u672c\u5927\u5730\u3001\u5927\u8535\u9686\u6587\u3001\u5e73\u585a\u7fa9\u5eb7\u3001\u4ed6\uff0eMRI\u62e1\u6563\u5f37\u8abf\u753b\u50cf\u304c\u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u306b\u6709\u7528\u3067\u3042\u3063\u305f\uff12\u75c7\u4f8b\u7b2c67\u56de\u65e5\u672c\u5fc3\u81d3\u75c5\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff08 9, \u540d\u53e4\u5c4b\uff09<\/li>\n
    18. \u7530\u4e2d\u5b8f\u660e\u3001\u798f\u5c71\u76f4\u7d00\u3001\u77f3\u4e38\u826f\u5e83. \u30b3\u30a4\u30eb\u585e\u6813\u5f8c\u306b\u814e\u9759\u8108\u8840\u6813\u75c7\u3001\u80ba\u8840\u6813\u585e\u6813\u75c7\u3092\u5408\u4f75\u3057\u305f\u814e\u52d5\u9759\u8108\u763b\u75c7\u4f8b.\u7b2c4\u56deJapan Peripheral Embolization Conference.(2019.9.\u672d\u5e4c)<\/li>\n
    19. \u4e95\u4e0a \u6b66\u3000GE PET\u30e6\u30fc\u30b6\u30fc\u30ba\u30df\u30fc\u30c6\u30a3\u30f3\u30b0 \u81e8\u5e8a\u7de8
      \n\u300e\u9593\u9055\u3048\u305f\u308a\u3001\u96e3\u3057\u304b\u3063\u305f\u75c7\u4f8b(\u982d\u981a\u90e8\u7de8)\u300fPET\u30b5\u30de\u30fc\u30bb\u30df\u30ca\u30fcin\u798f\u5cf6(2019.9 \u798f\u5cf6)<\/li>\n
    20. \u7530\u4e2d\u5b8f\u660e.\u816b\u760d\u6d78\u6f64\u306b\u3088\u308b\u8178\u9aa8\u52d5\u8108\u72ed\u7a84\u306b\u5bfe\u3057\u3066\u7d4c\u76ae\u7684\u30b9\u30c6\u30f3\u30c8\u30b0\u30e9\u30d5\u30c8\u6cbb\u7642\u3092\u884c\u3063\u305f1\u4f8b.\u7b2c2\u56deNEXT symposium.(2019.10,\u5948\u826f)<\/li>\n
    21. \u7530\u4e2d\u5b8f\u660e\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u6d25\u7530\u5b5d\u6cbb\u3001\u671b\u6708\u8f1d\u4e00, \u516b\u6749\u3000\u5de7. \u6c17\u7ba1\u8155\u982d\u52d5\u8108\u763b\u306e\u4e88\u5146\u51fa\u8840\u306b\u5bfe\u3057\u3066\u30d0\u30a4\u30a2\u30d0\u30fc\u30f3\u5185\u633f\u8853\u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u7b2c60\u56de\u65e5\u672c\u8108\u7ba1\u5b66\u4f1a\u7dcf\u4f1a.(2019.10.\u6771\u4eac)<\/li>\n
    22. Tsuruoka S, Kataoka M, Hamamoto Y, Ishikawa H, Takata N, Nagasaki K, Mochizuki T. Outcomes of definitive radiotherapy for stage I esophageal cancer (T1bN0M0). \u7b2c57\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2019. 10, \u798f\u5ca1)<\/li>\n
    23. \u6850\u5c71\u90c1\u5b50\uff0c\u7d30\u5ddd\u8cb4\u6676\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u7af9\u539f\u548c\u5b8f, \u5bfa\u672c\u5178\u5f18. Seromucinous borderline tumor\u306eFDG PET\/CT\u304a\u3088\u3073MRI\u6240\u898b. \u7b2c55\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a (2019.10.18-20, \u540d\u53e4\u5c4b)<\/li>\n
    24. \u7d30\u5ddd\u8cb4\u6676, \u9152\u4e95\u4f38\u4e5f, \u7d30\u5ddd\u6d69\u5e73, \u5fb7\u6c38\u4f38\u5b50, \u6850\u5c71\u90c1\u5b50, \u6e05\u6c34\u8f1d\u5f66, \u83c5\u539f\u656c\u6587, \u6e05\u91ce\u6b63\u666e, \u6749\u539f\u9032\u4ecb, \u7af9\u539f\u548c\u5b8f, \u5c71\u5143\u7bc4\u662d, \u5bfa\u672c\u5178\u5f18. \u5185\u819c\u75c7\u6027\u56a2\u80de\u8853\u5f8c\u306b\u767a\u751f\u3057\u305f\u5927\u8170\u7b4b\u660e\u7d30\u80de\u764c\u306e\uff11\u4f8b. \u7b2c55\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a (2019.10.18-20, \u540d\u53e4\u5c4b)<\/li>\n
    25. \u677e\u7530\u3000\u6075\u3001\u5ca1\u7530\u3000\u52a0\u5948\u5b50\u3001\u6751\u7530\u3000\u4eae\u6d0b\u3001\u6d77\u8001\u539f\u3000\u308b\u3044\u3001\u6d25\u7530\u3000\u5b5d\u6cbb\u3001\u671b\u6708\u3000\u8f1d\u4e00.Von Hippel-Lindau\u75c5\u306b\u5408\u4f75\u3057\u305fClear cell papillary cystadenoma(CCPC)\u306e1\u4f8b. \u7b2c55\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a(2019. 10, \u540d\u53e4\u5c4b)<\/li>\n
    26. \u9ad8\u7530\u7d00\u5b50, \u5bae\u5ddd\u6b63\u7537, \u5ddd\u53e3\u76f4\u4eba, \u57ce\u6238\u502b\u4e4b, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u5206\u5316\u578b\u7532\u72b6\u817a\u764c\u306b\u5bfe\u3059\u308b\u653e\u5c04\u6027\u30e8\u30fc\u30c9\u5185\u7528\u7642\u6cd5\u65bd\u884c\u4f8b\u306e\u80f8\u819c\u64ad\u7a2e\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c55\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u671f\u81e8\u5e8a\u5927\u4f1a (2019. 10, \u540d\u53e4\u5c4b)<\/li>\n
    27. Tsuruoka S, Kataoka M, Hamamoto Y, Ishikawa H, Takata N, Nagasaki K, Mochizuki T. Outcomes of definitive radiotherapy for stage I esophageal cancer (T1bN0M0). \u7b2c57\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2019. 10, \u798f\u5ca1)<\/li>\n
    28. \u974d\u5ca1\u614e\u592a\u90ce\u3001\u6ff1\u672c\u6cf0\u3001\u77f3\u5ddd\u6d69\u53f2\u3001\u9ad9\u7530\u7d00\u5b50\u3001\u9577\ufa11\u6167\u3001\u671b\u6708\u8f1d\u4e00\uff0e\u81a0\u82bd\u816b\u306e\u96c6\u5b66\u7684\u6cbb\u7642\u5f8c\u306b\u304a\u3051\u308b\u518d\u767a\u5f62\u5f0f\u306e\u691c\u8a0e\uff0e\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c32\u56de\u5b66\u8853\u5927\u4f1a\uff0e\uff08 11, \u540d\u53e4\u5c4b\uff09<\/li>\n
    29. \u5b89\u539f\u7f8e\u6587\u3001\u83ca\u6c60\u9686\u5fb3\u3001\u897f\u5ddd\u525b\u53f2\uff0e\u80f8\u90e8CT\u753b\u50cf\u304c\u9ad8\u7cbe\u7d30\u306b\u306a\u3063\u305f\u3053\u3068\u306b\u3088\u308b\u753b\u50cf\u8a3a\u65ad\u696d\u52d9\u3078\u306e\u5f71\u97ff\u306b\u3064\u3044\u3066\uff0e\u7b2c73\u56de\u56fd\u7acb\u75c5\u9662\u7dcf\u5408\u533b\u5b66\u4f1a\u3000\uff08 11, \u540d\u53e4\u5c4b\uff09<\/li>\n
    30. \u9ad8\u7530\u7d00\u5b50, \u6ff1\u672c\u6cf0, \u5bae\u5ddd\u6b63\u7537, \u77f3\u5ddd\u6d69\u53f2, \u974d\u5ca1\u614e\u592a\u90ce, \u9577\ufa11\u6167, \u671b\u6708\u8f1d\u4e00. \u7532\u72b6\u817a\u764c\u306b\u5bfe\u3059\u308b\u653e\u5c04\u6027\u30e8\u30fc\u30c9\u5185\u7528\u7642\u6cd5\u5f8c\u306e\u6551\u6e08\u653e\u5c04\u6027\u30e8\u30fc\u30c9\u5185\u7528\u7642\u6cd5\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c32\u56de\u5b66\u8853\u5927\u4f1a (2019. 11, \u540d\u53e4\u5c4b)<\/li>\n
    31. \u9ad8\u7530\u7d00\u5b50, \u5bae\u5ddd\u6b63\u7537, \u77f3\u6751\u96bc\u4eba, \u5ddd\u53e3\u76f4\u4eba, \u57ce\u6238\u502b\u4e4b, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. Salvage radioiodine therapy after adjuvant radioiodine therapy for differentiated thyroid cancer. \u7b2c59\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a (2019. 11, \u677e\u5c71)<\/li>\n
    32. \u5c0f\u91ce\u525b\u53f2\uff0c\u6a2a\u5cf0\u3000\u572d\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0eNon Local Mean\u30d5\u30a3\u30eb\u30bf\u3092\u5fdc\u7528\u3057\u305f\u30ce\u30a4\u30ba\u4f4e\u6e1b\u51e6\u7406\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066\u306e\u521d\u671f\u691c\u8a0e\uff0e\u7b2c59\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0811.1-3, \u677e\u5c71\uff09<\/li>\n
    33. \u7d30\u5ddd\u6d69\u5e73\uff0eClinical PET in Shikoku Cancer Center – current status and problem -\uff0e\u7b2c59\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0811.3, \u677e\u5c71\uff09<\/li>\n
    34. \u5ddd\u53e3\u76f4\u4eba. \u5fc3\u7b4b\u8840\u6d41PET\u306b\u304a\u3051\u308bRelative flow reserve\u3092\u7528\u3044\u305f\u865a\u8840\u8a55\u4fa1. \u7b2c59\u56de \u65e5\u672c\u6838\u533b\u5b66\u5b66\u4f1a\u7dcf\u4f1a \uff0811 \u677e\u5c71\uff09<\/li>\n
    35. \u7530\u4e2d \u653f\u884c, \u6771\u91ce \u535a, \u5ddd\u6761 \u6587\u9686, \u6c60\u6c34 \u6681\u5f66, \u4e2d\u7530 \u8302, \u4f0a\u7530 \u52dd\u5178, \u5bae\u7530 \u60a0\u91cc, \u85cf\u7530 \u65e9\u7d00, \u8c9e\u5fb3 \u307f\u3061\u3053, \u9e7f\u5cf6 \u6587, \u85e4\u679d \u88d5\u4e4b, \u963f\u90e8 \u5145\u4f2f. Step & Shoot\u6cd5\u3092\u7528\u3044\u305f\u6df1\u5438\u6c17\u606f\u6b62\u3081\u80ba\u8840\u6d41 \u7b2c39\u56de\u65e5\u672c\u6838\u533b\u6280\u8853\u5b66\u4f1a\u7dcf\u4f1a\u5b66\u8853\u5927\u4f1a\u30012019\u5e7411\u67082\u65e5\u3001\u677e\u5c71\u5e02\u7dcf\u5408\u30b3\u30df\u30e5\u30cb\u30c6\u30a3\u30bb\u30f3\u30bf\u30fc.<\/li>\n
    36. \u9e7f\u5cf6 \u6587\u3001\u6771\u91ce \u535a\u3001\u8535\u7530 \u65e9\u7d00\u3001\u5bae\u7530 \u60a0\u91cc\u3001\u8c9e\u5fb3 \u307f\u3061\u3053\u3001\u7530\u4e2d \u653f\u884c\u3001\u6c60\u6c34 \u6681\u5f66\u3001\u5ddd\u6761 \u6587\u9686\u3001\u4f0a\u7530 \u52dd\u5178\u3001\u677e\u672c \u767b\u4e16\u5b50\u3001\u963f\u90e8 \u5145\u4f2f. \u30bf\u30ea\u30a6\u30e0\u5fc3\u7b4b\u30b7\u30f3\u30c1\u30b0\u30e9\u30d5\u30a3\u30fc\u691c\u67fb\u5f8c\u306b\u56fd\u969b\u7a7a\u6e2f\u3067\u4e8b\u60c5\u3092\u8074\u53d6\u3055\u308c\u305f\u4e00\u4f8b. \u7b2c59\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012019\u5e7411\u67082\u65e5\u3001\u677e\u5c71\u5e02\u7dcf\u5408\u30b3\u30df\u30e5\u30cb\u30c6\u30a3\u30bb\u30f3\u30bf\u30fc.<\/li>\n
    37. \u5c71\u672c\u5c1a\u5e78\u3001\u4ed6\uff0e\u3000\u653e\u5c04\u7dda\u696d\u52d9\u5f93\u4e8b\u8005\u306b\u5bfe\u3059\u308b\u5065\u5eb7\u8a3a\u65ad\u306e\u3042\u308a\u65b9\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff5e\u6982\u8981\u3068\u30a2\u30f3\u30b1\u30fc\u30c8\u8abf\u67fb\u7d50\u679c\u306b\u3064\u3044\u3066\uff0e\u7b2c\uff12\u56de\u65e5\u672c\u653e\u5c04\u7dda\u5b89\u5168\u7ba1\u7406\u5b66\u4f1a\u30fb\u65e5\u672c\u4fdd\u5065\u7269\u7406\u5b66\u4f1a\u5408\u540c\u5927\u4f1a\uff082019\uff0e12\uff0e\u4ed9\u53f0\uff09<\/li>\n<\/ol>\n

      <\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/p>\n

        \n
      1. \u6cb3\u5185\u5b5d\u7bc4, \u7530\u9089\u88d5\u8cb4, \u6851\u539f\u5948\u90fd\u7f8e, \u5c71\u672c\u96c4\u592a, \u5409\u7530\u548c\u6a39, \u5e73\u4e95\u90a6\u660e, \u677e\u7530\u5353\u4e5f, \u5ddd\u53e3\u76f4\u4eba, \u57ce\u6238\u502b\u4e4b,\u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. Dynamic myocardial CT perfusion\u3092\u7528\u3044\u305f\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306e\u8a3a\u65ad\u306b\u304a\u3051\u308bcolor scale\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066. \u7b2c40\u56de\u305b\u3068\u3046\u3061\u5fc3\u81d3CT\u30fbMR\u52c9\u5f37\u4f1a. (2019.3 \u611b\u5a9b)<\/li>\n
      2. \u5409\u7530\u548c\u6a39\u3001\u7530\u908a\u88d5\u8cb4\u3001\u6cb3\u5185\u7fa9\u5f18\u3001\u6851\u539f\u5948\u90fd\u7f8e\u3001\u5ca1\u7530\u77e5\u4e45\u3001\u6cb3\u5185\u5b5d\u7bc4\u3001\u5e73\u4e95\u90a6\u660e\u3001\u5c71\u672c\u96c4\u592a\u3001\u4e2d\u6751\u58ee\u5fd7\u3001\u677e\u7530\u5353\u4e5f\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u5009\u7530\u8056\u3001\u57ce\u6238\u502b\u4e4b\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00. \u5e0c\u91c8\u9020\u5f71\u6cd5\u3092\u7528\u3044\u305f\u51a0\u52d5\u8108 CT \u306b\u304a\u3051\u308b\u30d7\u30e9\u30fc\u30af\u6027\u72b6\u3068 IB-IVUS \u306e\u6bd4\u8f03\u691c\u8a0e. \u7b2c39\u56de\u3057\u307e\u306a\u307f\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9. (2019.6 \u4eca\u6cbb)<\/li>\n
      3. \u6cb3\u5185\u7fa9\u5f18, \u4e95\u4e0a\u6b66, \u798f\u5c71\u76f4\u7d00, \u4e09\u6728\u5747, \u6d25\u7530\u5b5d\u6cbb, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u598a\u5a20\u4e2d\u306b\u8179\u58c1\u306b\u767a\u751f\u3057\u305fdesmoplastic small round cell tumor\u306e 1 \u4f8b. \u7b2c132\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff08 6, \u9ce5\u53d6\uff09<\/li>\n
      4. \u5c71\u672c\u5468\u5e73,\u5ca1\u7530\u77e5\u4e45,\u5e73\u4e95\u90a6\u660e,\u5409\u7530\u548c\u6a39,\u7530\u908a\u88d5\u8cb4,\u4e2d\u6751\u58ee\u5fd7,\u677e\u7530\u5353\u4e5f,\u5ddd\u53e3\u76f4\u4eba,\u57ce\u6238\u502b\u4e4b,\u57ce\u6238\u8f1d\u4ec1,\u5009\u7530\u8056,\u5bae\u5ddd\u6b63\u7537,\u671b\u6708\u8f1d\u4e00.\u5de6\u5ba4\u4e8c\u8154\u75c7\u306e1\u4f8b. \u7b2c 132 \u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a \u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a(2019.6,\u9ce5\u53d6)<\/li>\n
      5. \u7267\u7530\u61b2\u4e8c, \u6ff1\u672c\u6cf0, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb. \u5f53\u9662\u306b\u304a\u3051\u308b\u539f\u767a\u6027\u80ba\u764c\u306b\u5bfe\u3059\u308b\u5b9a\u4f4d\u7167\u5c04\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c132\u56de\u3000\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u3000\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2019. 6, \u9ce5\u53d6)<\/li>\n
      6. \u591a\u4fdd\u5eb7\u5e73, \u5ca1\u7530\u52a0\u5948\u5b50, \u6d77\u8001\u539f\u308b\u3044, \u677e\u7530\u6075, \u6d25\u7530\u5b5d\u6cbb, \u671b\u6708\u8f1d\u4e00. \u80ba\u5927\u7d30\u80de\u764c\u306b\u3088\u308b\u591a\u767a\u5c0f\u8178\u8ee2\u79fb\u306e\u4e00\u4f8b. \u7b2c132\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a \u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a. (2019.6, \u9ce5\u53d6)<\/li>\n
      7. \u7d30\u5ddd\u8cb4\u6676, \u5fb7\u6c38\u4f38\u5b50, \u7d30\u5ddd\u6d69\u5e73, \u6850\u5c71\u90c1\u5b50, \u6e05\u6c34\u8f1d\u5f66, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u672b\u4e45\u5f18, \u5c71\u4e0b\u7d20\u5f18, \u5bfa\u672c\u5178\u5f18. \u7570\u306a\u308b\u753b\u50cf\u6240\u898b\u3092\u793a\u3057\u305f\u786c\u5316\u6027\u80ba\u80de\u4e0a\u76ae\u816b\u306e\uff12\u4f8b. \u7b2c132\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2019.6.14, \u7c73\u5b50)<\/li>\n
      8. \u7d30\u5ddd\u8cb4\u6676, \u6850\u5c71\u90c1\u5b50, \u83c5\u539f\u656c\u6587, \u7267\u4f51\u6b69, \u4e0a\u91ce\u525b, \u672b\u4e45\u5f18, \u5c71\u4e0b\u7d20\u5f18, \u5c71\u5143\u7bc4\u662d, \u5bfa\u672c\u5178\u5f18. FDG\u9ad8\u96c6\u7a4d\u3092\u793a\u3057\u305f\u80baoncocytic carcinoid tumor\u306e\u4e00\u4f8b. \u7b2c54\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2019.6.15, \u7c73\u5b50) \u5e73\u585a\u7fa9\u5eb7\u3001\u4ed6\uff0e<\/li>\n
      9. \u5f53\u9662\u306b\u304a\u3051\u308b\u5168\u8eab\u62e1\u6563\u5f37\u8abf\u753b\u50cf\uff08DWIBS\uff09\u306e\u4f7f\u7528\u7d4c\u9a13\u3068\u305d\u306e\u6709\u7528\u6027 \u7b2c132\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff08 6, \u7c73\u5b50\uff09<\/li>\n
      10. \u7530\u4e2d\u5b8f\u660e. \u8179\u8154\u52d5\u8108\u72ed\u7a84\uff08MALS\u542b\u3080\uff09\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u3001\u51a0\u52d5\u8108\u6c17\u7ba1\u652f\u52d5\u8108\u543b\u5408\u75c7\u3001\u4eba\u5de5\u8840\u7ba1\u7f6e\u63db\u8853\u5f8c\u88ab\u8986\u7624\u58c1\u5897\u5927\u306b\u5bfe\u3059\u308b\u30d0\u30a4\u30a2\u30d0\u30fc\u30f3\u7559\u7f6e. \u56db\u56fdIVR\u30ea\u30b5\u30fc\u30c1\u30bb\u30df\u30ca\u30fc.(2019.8.\u677e\u5c71)<\/li>\n
      11. \u6cb3\u5185\u7fa9\u5f18, \u4e95\u4e0a\u6b66, \u60aa\u6027\u816b\u760d\u3068\u306e\u9451\u5225\u306b\u96e3\u6e0b\u3057\u305fPolypoid endometriosis\u306e1\u4f8b. \u677e\u5c71\u653e\u5c04\u7dda\u79d1\u533b\u4f1a \u7b2c25\u56de\u4f8b\u4f1a\uff08 8, \u611b\u5a9b\uff09<\/li>\n
      12. \u7530\u4e2d\u5b8f\u660e,\u5ddd\u53e3\u76f4\u4eba,\u671b\u6708\u8f1d\u4e00. \u8179\u90e8\u5927\u52d5\u8108\u7624\u4eba\u5de5\u8840\u7ba1\u7f6e\u63db\u8853\u5f8c\u306b\u88ab\u8986\u7624\u58c1\u5897\u5927\u3057\u30d0\u30a4\u30a2\u30d0\u30fc\u30f3\u30b9\u30c6\u30f3\u30c8\u30b0\u30e9\u30d5\u30c8\u5185\u633f\u8853\u306b\u3066\u6cbb\u7642\u3057\u305f2\u4f8b.\u7b2c33\u56de\u4e2d\u56fd\u56db\u56fdIVR\u7814\u7a76\u4f1a.(2019.11.\u5ca1\u5c71)<\/li>\n
      13. \u5ddd\u53e3\u76f4\u4eba\u3001\u7530\u4e2d\u5b8f\u660e\u3001\u671b\u6708\u8f1d\u4e00.\u9aa8\u9ac4\u7dda\u7dad\u75c7\u306b\u5408\u4f75\u3057\u305f\u80c3\u9759\u8108\u7624\u306b\u5bfe\u3057\u3066 B-RTO \u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u7b2c33\u56de\u4e2d\u56db\u56fdIVR\u7814\u7a76\u4f1a (2017.11, \u5ca1\u5c71)<\/li>\n
      14. \u6751\u7530\u4eae\u6d0b\uff0c\u7530\u4e2d\u5b8f\u660e\uff0c\u5ddd\u53e3\u76f4\u4eba\uff0c\u671b\u6708\u8f1d\u4e00. \u814e\u52d5\u9759\u8108\u763b\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u9650\u5c40\u6027\u306e\u814e\u9759\u8108\u8840\u6813\u75c7\u3092\u5408\u4f75\u3057\u305f1 \u4f8b. \u7b2c33\u56de\u4e2d\u56fd\u56db\u56fdIVR\u7814\u7a76\u4f1a.(2019.11.\u5ca1\u5c71)<\/li>\n
      15. \u5ca1\u7530 \u77e5\u4e45,\u5ddd\u53e3\u76f4\u4eba,\u7530\u9089\u88d5\u8cb4,\u4e2d\u6751\u58ee\u5fd7,\u677e\u7530\u5353\u4e5f,\u57ce\u6238\u502b\u4e4b,\u57ce\u6238\u8f1d\u4ec1,\u5009\u7530\u8056,\u5bae\u5ddd\u6b63\u7537,\u671b\u6708\u8f1d\u4e00.\u9577\u6642\u9593\u7d76\u98df\u30d7\u30ed\u30c8\u30b3\u30fc\u30ebFDG-PET\/CT\u3067\u8a3a\u65ad\u3055\u308c\u305f\u5fc3\u81d3\u9650\u5c40\u6027\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u306e\u753b\u50cf\u6240\u898b\u3068\u4e88\u5f8c\u306e\u691c\u8a0e.\u7b2c40\u56de \u3057\u307e\u306a\u307f\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9(2019.11,\u4eca\u6cbb)<\/li>\n
      16. \u6771\u91ce \u535a. \u30a2\u30c7\u30ce\u30b9\u30ad\u30e3\u30f3\u8ca0\u8377\u30bf\u30ea\u30a6\u30e0\u5fc3\u7b4b\u8840\u6d41\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u691c\u67fb\u5f8c\u306b\u56fd\u969b\u7a7a\u6e2f\u3067\u653e\u5c04\u7dda\u30c1\u30a7\u30c3\u30af\u3092\u53d7\u3051\u305f\u4e00\u4f8b. \u7b2c40\u56de\u3057\u307e\u306a\u307f\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u30012019\u5e7411\u670823\u65e5\u3001\u4eca\u6cbb\u56fd\u969b\u30db\u30c6\u30eb.<\/li>\n
      17. \u4e09\u6728\u3000\u5747.\u8133\u795e\u7d4c\u75be\u60a3\u306eMRI\u8a3a\u65ad\uff1a\u30eb\u30fc\u30c1\u30f3\u306b\u8ffd\u52a0\u3057\u305f\u3044\u64ae\u50cf\u6cd5 \u7b2c2\u56de\u611b\u5a9bMRI\u7814\u7a76\u4f1a(2019.11,\u611b\u5a9b)<\/li>\n
      18. \u6d66\u5ca1\u5927\u77e5,\u83ca\u6c60\u6075\u4e00,\u677e\u7530\u5065,\u68b6\u539f\u8aa0,\u4e95\u4e0a\u7950\u99ac,\u5c0f\u7530\u5c1a\u543e,\u4e09\u597d\u88d5\u7f8e,\u6d66\u5cf6\u96c4\u4ecb,\u7027\u672c\u7dbe\u9e7f.\u8133\u810a\u9ac4\u708e\u3067\u767a\u75c7\u3057\u3001\u7d4c\u904e\u3067\u8996\u795e\u7d4c\u708e\u3092\u751f\u3058\u305f\u6297MOG\u6297\u4f53\u95a2\u9023\u75be\u60a3\u306e\u4e00\u4f8b . \u7b2c133\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a \u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a. (2019.12, \u611b\u5a9b)<\/li>\n
      19. \u5fb7\u6c38\u4f38\u5b50, \u7d30\u5ddd\u8cb4\u6676\uff0c\u7d30\u5ddd\u6d69\u5e73, \u6850\u5c71\u90c1\u5b50, \u6e05\u6c34\u8f1d\u5f66, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u6749\u539f\u9032\u4ecb, \u5c71\u5143\u7bc4\u662d\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u5927\u6bbf\u7b4b\u5185\u306b\u767a\u751f\u3057\u305f\u60aa\u6027\u9846\u7c92\u7d30\u80de\u816b\u306e\uff11\u4f8b\uff0e\u7b2c133\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff0812.15, \u677e\u5c71\uff09<\/li>\n
      20. \u83ca\u6c60\u9686\u5fb3\u3001\u5b89\u539f\u7f8e\u6587\uff0e\u591a\u91cd\u69cb\u9020\u30d5\u30e9\u30c3\u30c8\u30d1\u30cd\u30eb\u88c5\u7f6e\u306e\u521d\u671f\u7d4c\u9a13\uff0e\u7b2c133\u56de\u3000\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u3000\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\u3000\uff08 12, \u677e\u5c71\uff09<\/li>\n
      21. \u300c\u9ad8\u9580\u653f\u5609, \u7af9\u53e3\u5d07, \u5ca9\u6751\u5353\u660e, \u539f\u4e95\u5ddd\u8c4a\u7ae0, \u798f\u4e95\u8061, \u6839\u6d25\u8ce2\u53f8, \u677e\u5f71\u662d\u4e00. \u7e26\u9694\u5185\u8840\u7ba1\u816b\u306e1\u4f8b.\u00a0\u7b2c133\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a \u4e2d\u56fd\uff65\u56db\u56fd\u5730\u65b9\u4f1a. (2019.12, \u611b\u5a9b)\u300d<\/li>\n
      22. \u9db4\u5ca1\u5e78\u592a,\u3000\u6d77\u8001\u539f\u308b\u3044,\u3000\u677e\u7530\u6075,\u3000\u5ca1\u7530\u52a0\u5948\u5b50,\u3000\u7530\u4e2d\u5b8f\u660e,\u3000\u6d25\u7530\u5b5d\u6cbb,\u3000\u671b\u6708\u8f1d\u4e00,\u3000\u4ed6.\u3000\u8853\u524d\u8a3a\u65ad\u304c\u56f0\u96e3\u3067\u3042\u3063\u305f\u9aa8\u76e4\u5185 Solitary fibrous tumor \u306e1\u4f8b.\u3000\u7b2c133\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\u3000\uff0812,\u3000\u611b\u5a9b\uff09<\/li>\n
      23. \u6f14\u8005\uff1a\u5c0f\u7530\u5c1a\u543e\u3001\u83ca\u6c60\u6075\u4e00\u3001\u6d66\u5ca1\u5927\u77e5\u3001\u7027\u672c\u7dbe\u9e7f\u3001\u4e09\u597d\u88d5\u5b9f\u3001\u4e95\u4e0a\u7950\u99ac\u3001\u68b6\u539f\u8aa0\u3001\u6d66\u5cf6\u96c4\u4ecb\u3001\u677e\u7530\u5065\u6f14\u984c\u540d\uff1a\u514d\u75ab\u4e0d\u5168\u95a2\u9023\u4e2d\u67a2\u795e\u7d4c\u30ea\u30f3\u30d1\u816b\u306e\u4e00\u4f8b\u5b66\u4f1a\u540d\uff1a\u7b2c133\u56de\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082019\u5e7412\u6708\uff09<\/li>\n
      24. \u5ca9\u91ce\u7965\u5b50(\u611b\u5a9b\u5927\u5b66\u533b\u5b66\u90e8\u3000\u653e\u5c04\u7dda\u533b\u5b66), \u5e73\u7530 \u96c5\u662d, \u5bd2\u5ddd \u9855\u6cbb, \u671b\u6708 \u8f1d\u4e00. \u6df1\u8178\u9aa8\u56de\u65cb\u52d5\u8108\u3092\u7d4c\u7531\u3057\u3066\u585e\u6813\u3057\u305ftype2 endoleak\u306e3\u4f8b. \u7b2c133\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a(2019. 12, \u611b\u5a9b)<\/li>\n
      25. \u7267\u7530\u61b2\u4e8c, \u6ff1\u672c\u6cf0, \u897f\u5d0e\u7d71, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb. \u90e8\u5206\u6458\u51fa\u8853\u3068\u8853\u5f8c\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u3092\u65bd\u884c\u3057\u305f\u810a\u7d22\u816b\u306e1\u4f8b. \u7b2c133\u56de\u3000\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u3000\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2019.12, \u611b\u5a9b)<\/li>\n
      26. \u5e73\u585a\u7fa9\u5eb7\u3001\u4ed6\uff0e\u4e0b\u80a2\u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u306e\u8a55\u4fa1\u306b\u304a\u3051\u308b\u5168\u8eab\u62e1\u6563\u5f37\u8abf\u753b\u50cf\uff08DWIBS\uff09\u306e\u6709\u7528\u6027\u7b2c133\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff08 12, \u677e\u5c71\uff09<\/li>\n
      27. \u7b2c50\u56de\u65e5\u672c\u6d88\u5316\u5668\u304c\u3093\u691c\u8a3a\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a\uff08\u4ee4\u548c\u5143\u5e7412\u6708\uff09\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff11\u300c\u4e2d\u56fd\u56db\u56fd\u652f\u90e850\u5e74\u306e\u6b69\u307f\u300d\u6d25\u7530\u3000\u5b5d\u6cbb\u3000\u611b\u5a9b\u770c\u652f\u90e8\u306b\u304a\u3051\u308b\u6d88\u5316\u5668\u304c\u3093\u691c\u8a3a\u306e50\u5e74<\/li>\n<\/ol>\n

        <\/a>\u25a0<\/span> \u8b1b\u6f14<\/strong><\/p>\n

          \n
        1. \u5c71\u672c\u5c1a\u5e78\uff0e\u77e5\u3063\u3066\u304a\u3053\u3046\uff01\u3055\u307e\u3056\u307e\u306a\u653e\u5c04\u7dda\u4e8b\u6545\uff0e\u88ab\u3070\u304f\u533b\u7642\u30b7\u30ea\u30fc\u30ba\u8b1b\u6f14\u4f1a\u246a\uff081\u3001\u4eac\u90fd\uff09<\/li>\n
        2. \u798f\u5c71\u76f4\u7d00. \u82e5\u624b\u533b\u5e2b\u306e\u305f\u3081\u306e\u809d\u7d30\u80de\u764c\u7d4c\u30ab\u30c6\u30fc\u30c6\u30eb\u6cbb\u7642. \u677e\u5c71\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\u7b2c19\u56de\u4f8b\u4f1a\uff082,\u611b\u5a9b\uff09<\/li>\n
        3. \u5c71\u672c\u5c1a\u5e78\uff0e\u904e\u53bb\u306b\u767a\u751f\u3057\u305f\u6c5a\u67d3\u30fb\u88ab\u3070\u304f\u4e8b\u6545\u306e\u4e8b\u4f8b\u306b\u3064\u3044\u3066\uff0e\u5973\u5ddd\u5730\u533a\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u8b1b\u6f14\u4f1a\uff082\u3001\u77f3\u5dfb\uff09<\/li>\n
        4. \u5c71\u672c\u5c1a\u5e78\uff0e\u6c5a\u67d3\u9632\u8b77\u88c5\u5099\u306e\u7740\u8131\u53ca\u3073GM\u30b5\u30fc\u30d9\u30a4\u30e1\u30fc\u30bf\u2015\u306e\u53d6\u6271\u3044\uff0e\u6771\u6d77\u5730\u533a\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u8b1b\u6f14\u4f1a\uff082\uff0e\u5927\u7515\uff09<\/li>\n
        5. \u57ce\u6238\u502b\u4e4b. \u5fc3\u81d3MRI\u306e\u57fa\u672c\u3068\u81e8\u5e8a\u5fdc\u7528. \u7b2c43\u56de\u5357\u4e88\u5faa\u74b0\u5668\u753b\u50cf\u7814\u7a76\u4f1a\u3000\u6559\u80b2\u8b1b\u6f14\uff08 2, \u611b\u5a9b\uff09<\/li>\n
        6. \u6e05\u6c34\u8f1d\u5f66\uff0e\u4e73\u764c\u306eMRI\u8a3a\u65ad\uff5e\u62e1\u304c\u308a\u8a3a\u65ad\u304b\u3089\u8cea\u7684\u8a3a\u65ad\u3078\uff5e\uff0e\u7b2c27\u56deCT\u30fbMR\u7814\u7a76\u4f1a\u3048\u3072\u3081\uff082.16, \u677e\u5c71\uff09<\/li>\n
        7. \u57ce\u6238\u8f1d\u4ec1\uff0eQPR: Quantitative Perfusion Ratio\u3092\u7528\u3044\u305fDynamic CT Perfusion\u89e3\u6790\uff0eWIC2019\uff082019\uff0e2\uff0c\u5ca9\u624b\uff09<\/li>\n
        8. Yuki Tanabe. 320row CT: Cutting edge Cardiac examination- From CCTA to Myocardial Dynamic CT perfusion -.Canon Luncheon symposium at ASCI 2019. <\/em>(2019. 3, Taipei<\/em>).<\/li>\n
        9. \u5c71\u672c\u5c1a\u5e78\uff0e\u673a\u4e0a\u6f14\u7fd2\u3000\u60f3\u5b9a\u554f\u984c\u306e\u30b0\u30eb\u30fc\u30d7\u8a0e\u8b70\uff0e\u798f\u5cf6\u770c\u539f\u5b50\u529b\u707d\u5bb3\u533b\u533b\u7642\u9023\u643a\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u4f1a\u8b70\u4e3b\u50ac\u300c\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u7814\u4fee\u300d\uff083\uff0e\u798f\u5cf6\uff09<\/li>\n
        10. \u57ce\u6238\u8f1d\u4ec1\uff0eCFR\u3092\u6975\u3081\u308b\uff1aCT\uff0eFRIENDS Live2019\uff082019\uff0e3\uff0c\u6771\u4eac\uff09<\/li>\n
        11. \u57ce\u6238\u502b\u4e4b. \u5fc3\u81d3CT\u30fbMRI\u306e\u57fa\u672c\u3068\u8aad\u5f71\u306e\u30dd\u30a4\u30f3\u30c8. \u7b2c38\u56de\u65e5\u672c\u753b\u50cf\u533b\u5b66\u4f1a\u3000\u7dcf\u5408\u8a3a\u7642\u30bb\u30df\u30ca\u30fc\uff08 3, \u6771\u4eac\uff09<\/li>\n
        12. \u7530\u4e2d\u5b8f\u660e.\u5e73\u6210\u306eIVR\u3092\u632f\u308a\u8fd4\u3063\u3066.\u7b2c49\u56de\u5fb3\u5cf6IVR\u7814\u7a76\u4f1a(2019.3.\u5fb3\u5cf6)<\/li>\n
        13. \u5009\u7530\u8056. \u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u6587\u732e\u30ec\u30d3\u30e5\u30fc. \u7b2c18\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u7814\u7a76\u4f1a\u30bb\u30df\u30ca\u30fc\uff082019, 4\u6708, \u5927\u962a\uff09<\/li>\n
        14. \u57ce\u6238\u8f1d\u4ec1\uff0e\u5fc3\u81d3CT\u306e\u30ec\u30dd\u30fc\u30c6\u30a3\u30f3\u30b0\u3068\u65b0\u6280\u8853\uff08CT Perfusion\u30fbFFR-CT\uff09\u306e\u6d3b\u7528\u6cd5\uff0e\u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff082019\uff0e4\uff0c\u6771\u4eac\uff09<\/li>\n
        15. \u5bae\u5ddd\u6b63\u7537. \u6559\u80b2\u8b1b\u6f14\u3000\u6838\u533b\u5b662: \u5fc3\u81d3 (\u975e\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306e\u6838\u533b\u5b66) Nuclear Cardiology for Non-Ischemic Heart Disease. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2019. 4, \u6a2a\u6d5c)<\/li>\n
        16. \u57ce\u6238\u502b\u4e4b. Compressed sensing\u306e\u6d3b\u7528. AIMS Cardiac Imaging 2019\u3000\u6559\u80b2\u8b1b\u6f14\uff08 5, \u6771\u4eac\uff09<\/li>\n
        17. \u5c71\u672c\u5c1a\u5e78\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306e\u670d\u7528\u3068\u52b9\u679c\u3000\u4ed6\uff0e\u798f\u5ca1\u770c\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u914d\u5e03\u306b\u95a2\u3059\u308b\u7814\u4fee\u4f1a\uff085\uff0e\u7cf8\u5cf6\uff09<\/li>\n
        18. \u5c71\u672c\u5c1a\u5e78\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306e\u670d\u7528\u3068\u52b9\u679c\u3000\u4ed6\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306b\u95a2\u3059\u308b\u533b\u7642\u5f93\u4e8b\u8005\u5411\u3051\u7814\u4fee\u4f1a\uff086\uff0e\u677e\u6c5f\uff09<\/li>\n
        19. \u7530\u908a\u3000\u88d5\u8cb4\uff0e\u300c\u865a\u8840\u306e\u8a55\u4fa1\u300d\u301c\u975e\u4fb5\u8972\u8a3a\u65ad\uff08\u30b7\u30f3\u30c1\u30fbperfusion CTCA\uff09\u3002ADATARA-Live Demonstration 2019.\uff08 6, \u798f\u5cf6\uff09<\/li>\n
        20. \u57ce\u6238\u8f1d\u4ec1\uff0e\u5fc3\u81d3CT\u306e\u65b0\u305f\u306a\u6f6e\u6d41\u301cCT Perfusion\u3092\u81e8\u5e8a\u306b\u6d3b\u304b\u3059\u301c\uff0e\u7b2c18\u56de\u9ad8\u901f\u3089\u305b\u3093CT\u6280\u8853\u30bb\u30df\u30ca\u30fc\uff082019\uff0e6\uff0c\u5e83\u5cf6\uff09<\/li>\n
        21. \u5ddd\u53e3\u76f4\u4eba. \u5fc3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u306e\u753b\u50cf\u8a3a\u65ad. \u7b2c41\u56de\u611b\u5a9b\u5fc3\u81d3\u6838\u533b\u5b66\u8ac7\u8a71\u4f1a \uff086 \u677e\u5c71\uff09<\/li>\n
        22. \u57ce\u6238\u8f1d\u4ec1\uff0eCT perfusion\u3067\u865a\u8840\u3092\u8a3a\u308b\uff0e\u7b2c\u4e00\u56de\u7409\u7403\u5927\u5b66\u5fc3\u81d3CT\u30bb\u30df\u30ca\u30fc\uff082019\uff0e7\uff0c\u6c96\u7e04\uff09<\/li>\n
        23. \u57ce\u6238\u502b\u4e4b.\u5fc3\u81d3MRI\u306e\u57fa\u672c\u304b\u3089Compressed sensing\u304c\u3082\u305f\u3089\u3059\u65b0\u305f\u306a\u53ef\u80fd\u6027. \u7b2c20\u56de\u590f\u5b63\u6280\u8853\u5b66\u4f1aMR\u7814\u7a76\u4f1a\u3000\u7279\u5225\u8b1b\u6f14\uff08 7, \u5ca1\u5c71\uff09<\/li>\n
        24. \u83c5\u539f\u656c\u6587\uff0ePET-CT\u3000\u7279\u5fb4\u3068\u30d4\u30c3\u30c8\u30d5\u30a9\u30fc\u30eb\uff0e\u7b2c27\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a(2019.7.13, \u65b0\u5bbf)<\/li>\n
        25. \u5c71\u672c\u5c1a\u5e78\uff0e\u75c5\u9662\u306b\u304a\u3051\u308b\u6c5a\u67d3\u50b7\u75c5\u8005\u306e\u53d7\u5165\uff08\u8a73\u7d30\u7de8\uff09\uff0e\u5927\u9593\u75c5\u9662\u8b1b\u6f14\u4f1a\uff087\uff0e\u5927\u9593\uff09<\/li>\n
        26. \u83ca\u6c60\u6075\u4e00.\u30003D-FLAIR\u3068\u5727\u7e2e\u30bb\u30f3\u30b7\u30f3\u30b0.\u00a0 \u677e\u5c71\u653e\u5c04\u7dda\u79d1\u533b\u4f1a.\u3000(2019.8.2, \u677e\u5c71)<\/li>\n
        27. \u7530\u4e2d\u5b8f\u660e.TACE\u3092\u542b\u3081\u305f\u8840\u7ba1\u585e\u6813\u8853.JMS\u8b1b\u6f14\u4f1a.(2019.8.\u5e83\u5cf6)<\/li>\n
        28. \u5c71\u672c\u5c1a\u5e78\uff0e\u653e\u5c04\u7dda\u306e\u304a\u306f\u306a\u3057\uff0e\u611b\u5a9b\u770c\u8eab\u306e\u56de\u308a\u306e\u653e\u5c04\u7dda\u6e2c\u5b9a\u4f53\u9a13\u6559\u5ba4\uff088\uff0e\u65b0\u5c45\u6d5c\uff09<\/li>\n
        29. \u5c71\u672c\u5c1a\u5e78\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306e\u670d\u7528\u3068\u52b9\u679c\u3000\u4ed6\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306b\u4fc2\u308b\u533b\u7642\u5f93\u4e8b\u8005\u5411\u3051\u7814\u4fee\u4f1a\uff088\uff0e\u7c73\u5b50\uff09<\/li>\n
        30. \u7530\u908a\u3000\u88d5\u8cb4\uff0e\u51a0\u52d5\u8108\u30d7\u30e9\u30fc\u30af\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u3002PCSK9Special\u00a0Seminar\u00a0in Shikoku\u3002\uff08 8, \u677e\u5c71\uff09<\/li>\n
        31. \u57ce\u6238\u502b\u4e4b. \u5fc3\u819c\u75be\u60a3. SCMR Japan WG Seminar 2018\u3000\u30df\u30cb\u30ec\u30af\u30c1\u30e3\u30fc\uff08 8, \u6771\u4eac\uff09<\/li>\n
        32. \u57ce\u6238\u502b\u4e4b. Compressed sensing for Cardiac MR. \u7b2c47\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u5927\u4f1a\u3000\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff08 9, \u718a\u672c\uff09<\/li>\n
        33. \u7247\u5ca1\u6b63\u660e\u3001\u653e\u5c04\u7dda\u6cbb\u7642\uff1a\u73fe\u72b6\u3068\u6700\u8fd1\u306e\u9032\u6b69\uff08 9, \u5b87\u548c\u5cf6\u5e02\u7acb\u75c5\u9662\uff09<\/li>\n
        34. \u83c5\u539f\u656c\u6587\uff0e\u300c\u304c\u3093\u300d\u306b\u3064\u3044\u3066\uff5e\u77e5\u3063\u3066\u304a\u3044\u3066\u307b\u3057\u3044\u3053\u3068\uff5e\uff0e\u611b\u5a9b\u770c\u304c\u3093\u6559\u80b2\u63a8\u9032\u5354\u8b70\u4f1a\u8b1b\u6f14 (2019.9.12, \u897f\u6761)<\/li>\n
        35. \u5c71\u672c\u5c1a\u5e78\uff0e\u533b\u7642\u8005\u304c\u77e5\u3063\u3066\u304a\u304f\u3079\u304d\u539f\u5b50\u529b\u9632\u707d\u306e\u77e5\u8b58\uff0e\u88ab\u3070\u304f\u533b\u7642\u30b7\u30ea\u30fc\u30ba\u8b1b\u6f14\u4f1a\u246b\uff089\u3001\u4eac\u90fd\uff09<\/li>\n
        36. \u5c71\u672c\u5c1a\u5e78\uff0e\u539f\u5b50\u529b\u707d\u5bb3\u533b\u7642\u5354\u529b\u6a5f\u95a2\u7814\u4fee\uff0810\u3001\u897f\u6761\uff09<\/li>\n
        37. \u5c71\u672c\u5c1a\u5e78\uff0e\u73fe\u5728\u306e\u798f\u5cf6\u6d5c\u901a\u308a\u5730\u57df\u306e\u4e00\u822c\u533b\u7642\u72b6\u6cc1\uff0e\u65b0\u6f5f\u5730\u533a\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u8b1b\u6f14\u4f1a\uff0810\uff0e\u67cf\u5d0e\uff09<\/li>\n
        38. \u5c71\u672c\u5c1a\u5e78\uff0e\u539f\u5b50\u529b\u707d\u5bb3\u6642\u306b\u304a\u3051\u308b\u653e\u5c04\u7dda\u306e\u5065\u5eb7\u5f71\u97ff\u306b\u3064\u3044\u3066\uff0e\u653e\u5c04\u7dda\u306b\u3088\u308b\u5065\u5eb7\u5f71\u97ff\u7b49\u306b\u95a2\u3059\u308b\u7814\u4fee\u4f1a\uff0810\uff0e\u5c0f\u6a3d\uff09<\/li>\n
        39. \u5bae\u5ddd\u6b63\u7537, \u4e95\u4e0a\u3000\u6b66. \u611b\u5a9b\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u5fc3\u81d3\uff30\uff25\uff34\u691c\u67fb\u306b\u3064\u3044\u3066. \u7b2c25 \u56de \u30b5\u30a4\u30d7\u30ea\u30b9\u6280\u8853\u4ea4\u6d41\u4f1a (2019.10, \u677e\u5c71)<\/li>\n
        40. \u5c0f\u5ddd\u907c\u3000Machine learning, Blockchain\u6280\u8853\u3092\u4f7f\u7528\u3057\u305f\u653e\u5c04\u7dda\u79d1\u533b\u306e\u696d\u52d9. \u677e\u5c71\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\uff082019, 10\u6708\uff09<\/li>\n
        41. \u57ce\u6238\u502b\u4e4b. \u8a73\u3057\u3044\u3053\u3068\u306f\u3088\u304f\u5206\u304b\u308a\u307e\u305b\u3093\u304c\u5fc3\u81d3MRI\u306e\u8aad\u5f71\u3092\u6559\u3048\u3066\u4e0b\u3055\u3044. \u7b2c55\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\u3000\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff08 10, \u540d\u53e4\u5c4b\uff09<\/li>\n
        42. \u5009\u7530\u8056. \u5fc3\u81d3CT\u3092\u7528\u3044\u305f\u5fc3\u8840\u7ba1 3D \u30d7\u30ea\u30f3\u30c6\u30a3\u30f3\u30b0\u30e2\u30c7\u30eb. ECHO AWAJI CV IMAGING 2019\uff082019, 11 \u6708, \u5175\u5eab\uff09<\/li>\n
        43. \u7530\u4e2d\u5b8f\u660e.EHIME\u30b9\u30bf\u30a4\u30eb\u80ba\u5bae\u5d0eIVR\u7814\u7a76\u4f1a(2019.11.\u5bae\u5d0e)<\/li>\n
        44. \u7530\u4e2d\u5b8f\u660e. \u8840\u7ba1\u640d\u50b7\u306b\u5bfe\u3059\u308bIVR\u3000\u30d0\u30a4\u30a2\u30d0\u30fc\u30f3 \u30b9\u30c6\u30f3\u30c8\u30b0\u30e9\u30d5\u30c8\u306e\u81e8\u5e8a\u6210\u7e3e\u3068Technical Tips.(2019.11.\u5ca1\u5c71)<\/li>\n
        45. \u5c0f\u5ddd\u907c\u3000\u4eba\u5de5\u77e5\u80fd\u3092\u7528\u3044\u305f\u653e\u5c04\u7dda\u79d1\u696d\u52d9\u3078\u306e\u5fdc\u7528. \u7b2c6\u56de\u81e8\u5e8a\u8907\u96d1\u7cfb\u30fb\u30d5\u30e9\u30af\u30bf\u30eb\u89e3\u6790\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff082019, 11\u6708\uff09<\/li>\n
        46. \u7530\u908a\u3000\u88d5\u8cb4\uff0eCT perfusion\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u865a\u8840\u8a55\u4fa1\u3002\u7b2c59\u56de\u65e5\u672c\u6838\u533b\u5b66\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u3000\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff12\u3002\uff08 11, \u677e\u5c71\uff09<\/li>\n
        47. \u6771\u91ce \u535a. \u5352\u5f8c\u6559\u80b2\u30d7\u30ed\u30b0\u30e9\u30e01 \u5c02\u9580\u6280\u5e2b\u5bfe\u8c61\u8b1b\u5ea7\u300c\u5fc3\u81d3\u300d\u5fc3\u7b4b\u8840\u6d41SPECT\u691c\u67fb\u3068\u8a3a\u65ad. \u7b2c39\u56de\u65e5\u672c\u6838\u533b\u6280\u8853\u5b66\u4f1a\u7dcf\u4f1a\u5b66\u8853\u5927\u4f1a\u30012019\u5e7411\u67082\u65e5\u3001\u677e\u5c71\u5e02\u7dcf\u5408\u30b3\u30df\u30e5\u30cb\u30c6\u30a3\u30bb\u30f3\u30bf\u30fc.<\/li>\n
        48. \u6771\u91ce \u535a. \u30c6\u30ad\u30b9\u30c8\u89e3\u8aac \u7dcf\u8ad6. \u7b2c13\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u533a\u5730\u57df\u5225\u6559\u80b2\u7814\u4fee\u4f1a\u30012019\u5e7411\u67089\u65e5\u3001\u5009\u6577\u4e2d\u592e\u75c5\u9662\u4ed8\u5c5e\u4e88\u9632\u533b\u7642\u30d7\u30e9\u30b6\u53e4\u4e45\u8cc0\u30db\u30fc\u30eb.<\/li>\n
        49. \u798f\u5c71\u76f4\u7d00. \u5352\u5f8c\u6559\u80b2\u30d7\u30ed\u30b0\u30e9\u30e0\u3000\u5c02\u9580\u6280\u5e2b\u5bfe\u8c61\u8b1b\u5ea7\u300c\u5fc3\u81d3\u300d\u3000\u5fc3\u81d3PET\/CT\u691c\u67fb\u3068\u8a3a\u65ad. \u7b2c39\u56de\u65e5\u672c\u6838\u533b\u5b66\u6280\u8853\u5b66\u4f1a\u7dcf\u4f1a\u5b66\u8853\u5927\u4f1a\uff0811,\u611b\u5a9b\uff09<\/li>\n
        50. \u5e73\u585a\u7fa9\u5eb7\uff0e\u7b2c28\u56de\u4e2d\u56fd\u30fb\u56db\u56fdNR\u7814\u7a76\u4f1a\u306e\u75c7\u4f8b\u3092\u632f\u308a\u8fd4\u3063\u3066 \u7b2c29\u56de\u4e2d\u56fd\u30fb\u56db\u56fdNR\u7814\u7a76\u4f1a\uff0811, \u9ad8\u677e\uff09<\/li>\n
        51. \u5c71\u672c\u5c1a\u5e78\uff0e\u539f\u5b50\u529b\u707d\u5bb3\u533b\u7642\u306e\u52d5\u5411\u306b\u3064\u3044\u3066 \u4f0a\u65b9\u5730\u533a\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u8b1b\u6f14\u4f1a\uff0811. \u516b\u5e61\u6d5c\uff09<\/li>\n
        52. \u5ddd\u53e3\u76f4\u4eba. \u6559\u80b2\u30bb\u30df\u30ca\u30fc\u30fbIVR\u7dcf\u8ad6\u3000\u7b2c133\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\u5730\u65b9\u4f1a\uff0812 \u677e\u5c71\uff09<\/li>\n
        53. \u5009\u7530\u8056. 3D \u30e2\u30c7\u30eb\u306b\u95a2\u3059\u308b\u4e16\u754c\u306e\u6587\u732e\u30ec\u30d3\u30e5\u30fc\u3068\u5f01\u819c\u75c7 3D \u30e2\u30c7\u30eb\u306e\u5831\u544a\uff0e\u7b2c19\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u7814\u7a76\u4f1a\u30bb\u30df\u30ca\u30fc\uff082019, 12\u6708\uff0c\u5927\u962a\uff09<\/li>\n
        54. \u5c71\u672c\u5c1a\u5e78\uff0e\u4f4f\u6c11\u306b\u5bfe\u3059\u308b\u75c5\u9662\u5916\u3067\u306e\u533b\u7642\u5bfe\u5fdc\uff0e\u5e83\u5cf6\u5927\u5b66\u4e2d\u6838\u4eba\u6750\u80b2\u6210\u7814\u4fee\u4f1a\uff0812\uff0e\u5e83\u5cf6\uff09<\/li>\n
        55. \u5c71\u672c\u5c1a\u5e78\uff0e\u798f\u5cf6\u7b2c\u4e00\u4e8b\u6545\u306e\u5730\u57df\u533b\u7642\u3078\u306e\u5f71\u97ff\u3068\u539f\u5b50\u529b\u707d\u5bb3\u533b\u533b\u7642\u4f53\u5236\u306e\u52d5\u5411\uff0e\u9577\u6d5c\u8d64\u5341\u5b57\u75c5\u9662\u7814\u4fee\u4f1a\uff0812\uff0e\u9577\u6d5c\uff09<\/li>\n
        56. \u5c71\u672c\u5c1a\u5e78\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306e\u52b9\u80fd\u7b49\u306b\u3064\u3044\u3066\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u5099\u84c4\u306b\u4fc2\u308b\u8aac\u660e\u4f1a\uff0812\uff0e\u677e\u6c5f\uff09<\/li>\n
        57. \u5c71\u672c\u5c1a\u5e78\uff0e\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u306e\u57fa\u790e\uff0e\u5c0f\u6d5c\u5730\u533a\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u8b1b\u6f14\u4f1a\uff0812\uff0e\u5c0f\u6d5c\uff09<\/li>\n
        58. \u5c71\u672c\u5c1a\u5e78\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306e\u914d\u5e03\u30fb\u670d\u7528\u306b\u5f53\u305f\u3063\u3066\u306e\u6539\u6b63\u306e\u30dd\u30a4\u30f3\u30c8\u3068\u3053\u308c\u307e\u3067\u306e\u7d4c\u7def.\u5cf6\u6839\u770c\u539f\u5b50\u529b\u707d\u5bb3\u533b\u7642\u95a2\u4fc2\u6a5f\u95a2\u9023\u7d61\u4f1a\u8b70\uff0812\uff0e\u677e\u6c5f\uff09<\/li>\n
        59. \u5c71\u672c\u5c1a\u5e78\uff0e\u653e\u5c04\u7dda\u306b\u3088\u308b\u4eba\u4f53\u3078\u306e\u5f71\u97ff\uff5e\u653e\u5c04\u7dda\u9632\u8b77\u306e\u65b9\u6cd5\uff5e\uff0e\u96fb\u6e90\u5730\u57df\u632f\u8208\u30bb\u30f3\u30bf\u30fc\u8b1b\u6f14\u4f1a\uff0812\uff0e\u65b0\u6f5f\uff09<\/li>\n<\/ol>\n

          <\/a>\u25a0<\/span> \u7814\u7a76\u52a9\u6210<\/strong>
          \n1. \u5bae\u5ddd\u6b63\u7537. \u65e5\u672c\u5b66\u8853\u632f\u8208\u4f1a \u79d1\u7814\u8cbb \u57fa\u76e4\u7814\u7a76(C) \u5fc3\u623f\u7d30\u52d5\u306e\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u3068\u3057\u3066\u306ePET\u304a\u3088\u3073\u534a\u5c0e\u4f53SPECT\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e (H29\u5e74\uff5eH31\u5e74\u3000\u7814\u7a76\u4ee3\u8868\u8005)
          \n          <\/a>\u25a0<\/span>\u00a0\u53d7\u8cde<\/strong><\/p>\n

            \n
          1. \u5009\u7530\u8056.Best Reviewer Award 2019 (European Society of Radiology, 25th<\/sup> European Congress of Radiology, Wien, Austria, February 27- March 3, 2019)<\/li>\n
          2. \u6cb3\u5185\u7fa9\u5f18. \u7b2c78\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1aCyPos\u8cde Bronze Medal<\/li>\n
          3. \u5409\u7530\u548c\u6a39\u3000\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1aYIA\u6700\u512a\u79c0\u8cde(\u653e\u5c04\u7dda\u90e8\u9580)<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

            2019\u5e74\u696d\u7e3e\u3000\u305d\u306e2 \u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868 \u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09 \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09 \u25a0 \u8b1b\u6f14 \u25a0 \u7814\u7a76\u52a9\u6210 \u25a0 \u53d7\u8cde \u8ad6\u6587\u3001\u56fd\u969b\u5b66\u4f1a\u767a\u8868\u306f2019\u5e74\u696d\u7e3e\u3000\u305d\u306e1\u3092\u3054\u89a7\u4e0b\u3055\u3044\u3002   \u25a0 \u5b66\u4f1a\u767a\u8868(\u56fd\u5185) \u25cf \u56fd\u5185 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-5193","post","type-post","status-publish","format-standard","hentry","category-20"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts\/5193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/comments?post=5193"}],"version-history":[{"count":0,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts\/5193\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/media?parent=5193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/categories?post=5193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/tags?post=5193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}